Abstracts tagged "spondyloarthritis"

Abstract Number: 2119 • ACR Convergence 2024
IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures
Chloe Heiting¹, Donald McMahon¹, Douglas Mintz¹, Weijia Yuan¹, Insa Mannstadt¹, Linda A Russell¹, Emily Stein¹, Dalit Ashany² and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Scarsdale, NY, ³Hospital for Special Surgery, New York 10025, NY
Background/Purpose: Axial spondyloarthritis (AxSpA) is characterized by abnormal bone formation and, paradoxically, bone loss accompanied by increased bone fragility and vertebral fracture risk. Tumor necrosis…
Abstract Number: 2364 • ACR Convergence 2024
Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
Marina Magrey¹, Denis Poddubnyy², Mark Lebwohl³, Rajan Bajracharya⁴, Dirk de Cuyper⁵, Alexander Marten⁶, Luke Peterson⁷, Jeffrey L. Stark⁸ and Joseph F. Merola⁹, ¹Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ²Charite-Universitatsmedizin Berlin, Berlin, Germany, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Morrisville, NC, ⁸UCB Pharma, Smyrna, GA, ⁹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Anxiety and depression are highly prevalent in patients (pts) with axial spondyloarthritis (axSpA)/PsA.1,2 We report mental health data in pts with axSpA/PsA from trials…
Abstract Number: 0231 • ACR Convergence 2024
Imaging Characteristics and Demographic Variations in Patients with Axial Spondylarthritis, Axial Psoriatic Arthritis, and Inflammatory Bowel Disease-Related Arthritis with Axial Involvement: Insights from a Single Center at Cleveland Clinic Abu Dhabi
Rajaie Namas¹, Ahlam Almarzooqi², Sarah Al Qassimi³ and Esat Memisoglu³, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Emirates Health Services, Sharjah, United Arab Emirates, ³Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Background/Purpose: Spondyloarthropathies (SpAs) are a group of seronegative, inflammatory arthritides, including axial spondylarthritis (ax-SpA), axial psoriatic arthritis (ax-PsA), and inflammatory bowel disease related arthritis with…
Abstract Number: 0547 • ACR Convergence 2024
EspANDE Project: Improvement of Primary Care-Rheumatology Coordination in Spondyloarthritis in a Health Area in Northern Spain
Julio Sánchez-Martín¹, Cristina Martinez-Dubois², Javier Rueda Gotor³, Gabriel Pinedo-Lopez², Alvaro Perez-Martin², Roberto Gonzalez-Santamaria², Belén Atienza-Mateo⁴, Vanesa Calvo-Rio⁵, Inigo Gonzalez-Mazon⁶, Natalia Palmou Fontana⁴, Enriqueta Peiro-Callizo², Diana Prieto-Peña⁴, Lara Sanchez Bilbao⁷, Fernando Lopez-Gutierrez⁸ and Ricardo Blanco-Alonso⁹, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³Hospital Sierrallana, Torrelavega, Cantabria, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ⁵Valdecilla Hospital, Santander, Cantabria, Spain, ⁶H. U. Marques de Valdecilla, Santander, Cantabria, Spain, ⁷Rheumatology and Ophthalmology. Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Spondyloarthritis (SpA) constitutes a diverse set of inflammatory rheumatic diseases with a prevalence of 1.9% in the general population. Diagnostic delay, identified as a…
Abstract Number: 0565 • ACR Convergence 2024
Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study
Anthony Lichaa¹, Pauline KRUG¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive disease, characterized by chronic inflammation and progressive structural damage. However, the kinetic of progression to ankylosis and much…
Abstract Number: 0599 • ACR Convergence 2024
Sex- related Differences in Efficacy of Biologics in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
Haseeb Chaudhary¹, Omer Pamuk², Sarah Abi Doumeth³, Ansaam Daoud⁴, Muhammad Shamim⁵ and Marina Magrey⁶, ¹Case Western Reserve University, Westlake, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ³Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland Heights, OH, ⁴Case Western Reserve University/University Hospitals, Akron, OH, ⁵University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁶Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: There is limited information about sex-related differences in efficacy of biologics in axial spondyloarthritis (axSpA). We hypothesized that females with axSpA are less likely…
Abstract Number: 1433 • ACR Convergence 2024
Association of Contextual Factors with Sonographic Inflammatory and Structural Phenotypes in Psoriatic Arthritis Patients
Andre Lucas Ribeiro¹, Sydney Thib², Kangping Cui³, Sahil Koppikar⁴ and Lihi Eder⁵, ¹Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, ²Women's College Research Institute, Toronto, Canada, ³Sunnybrook Hospital, Toronto, Gravenhurst, ON, Canada, ⁴Women's College Hospital & University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Ultrasound (US) is a valuable tool for enhancing disease activity assessment in psoriatic arthritis (PsA) by providing detailed visualization of both inflammatory and structural…
Abstract Number: 1480 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Victoria Navarro Compán¹, Maureen Dubreuil², Karl Gaffney³, Jonathan Kay⁴, Christine de la Loge⁵, Ute Massow⁶, Vanessa Taieb⁷, Thomas Vaux⁸ and Atul Deodhar⁹, ¹La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ²Section of Rheumatology, Boston University School of Medicine, Boston, MA, ³Health Care - NHS, Norwich, United Kingdom, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Slough, United Kingdom, ⁹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In the phase 3 BE MOBILE 1 and 2 studies, bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits interleukin (IL)-17F in addition to IL-17A,…
Abstract Number: 2155 • ACR Convergence 2024
Direct Comparison of Sleep Quality and Risk Factors for Poor Sleep Across Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis
Dagna Polak¹, Mateusz Wilk², Piotr Kuszmiersz¹, Glenn Haugeberg³, Mariusz Korkosz⁴ and Zofia Guła⁴, ¹University Hospital in Cracow, Kraków, Poland, ²Univesity Hospital in Cracow, Kraków, Poland, ³Sørlandet Hospital, Kristiansand, Kristiansand, Norway, ⁴Department of Rheumatology and Immunology, Jagiellonian University Medical College, Kraków, Poland

Background/Purpose: Sleep disorders are common among patients with inflammatory arthritis (IA) and have probably bilateral influence on disease activity and quality of life. Pathomechanism of…
Abstract Number: 2367 • ACR Convergence 2024
Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
Philip Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Alexander Marten⁴, Ute Massow⁴, Vishvesh Shende³, Myriam Manente⁵, Luke Peterson⁶, Katy White³, Peter Nash⁷ and Lianne S Gensler⁸, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Charite-Universitatsmedizin Berlin, Berlin, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim am Rhein, Germany, ⁵UCB Pharma, Braine-l'Alleud, Belgium, ⁶UCB Pharma, Morrisville, NC, ⁷School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ was generally well tolerated by patients (pts)…
Abstract Number: 0234 • ACR Convergence 2024
MRI of Sacroiliac Joints: Is Contrast Necessary for the Detection of Sacroiliitis?
Damira Sereda¹, Arun Venkataraman¹, Harlan Stock¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Spondyloarthropathy (SpA) encompasses several conditions, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis, arthritis linked with inflammatory bowel disease, and undifferentiated spondyloarthritis [1]. Sacroiliitis…
Abstract Number: 0548 • ACR Convergence 2024
Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
David Kiefer¹, Juergen Braun², Uta Kiltz³, Niklas Kolle¹, Lucia Schneider¹, Ioana Andreica⁴, Bjoern Buehring⁵, Philipp Sewerin⁶, Imke Redeker⁷, Styliani Tsiami⁸, Susanne Herbold⁹ and Xenofon Baraliakos⁸, ¹Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁵Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, ⁶Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Ruhr Universität Bochum, Bochum, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Herne, Germany
Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
Abstract Number: 0566 • ACR Convergence 2024
How Early Is Early? Unveiling Time to Diagnosis Since Symptom Onset and Its Determinants in Patients Suspected of Early Axial Spondyloarthritis: Data from the SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy Marques¹, Desiree van der Heijde², Liese de Bruin³, Miranda van Lunteren⁴, Robert Landewé⁵, Karen Minde Fagerli⁶, Maikel Van Oosterhout⁷, Floris van Gaalen⁸ and Sofia Ramiro⁹, ¹Leiden University Medical Center, Coimbra, Zuid-Holland, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ⁵Amsterdam University Medical Center, Meerssen, Netherlands, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, the Netherlands, Gouda, Netherlands, ⁸LUMC, Leiden, Zuid-Holland, Netherlands, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Patients with chronic back pain (CBP) of less than two-years (2y) duration suspected of axial spondyloarthritis (axSpA) referred to the rheumatologist can be reliably…
Abstract Number: 0602 • ACR Convergence 2024
Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
Joseph F. Merola¹, Philip Mease², Atul Deodhar³, Alice Gottlieb⁴, Barbara Ink⁵, Dirk de Cuyper⁶, Rajan Bajracharya⁵, Jérémy Lambert⁷, Jason Coarse⁸ and Laura Coates⁹, ¹UT Southwestern Medical Center, Dallas, TX, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Morrisville, NC, ⁹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) domain‑based treatment recommendations for PsA focus on six key domains: peripheral arthritis, axial…
Abstract Number: 1434 • ACR Convergence 2024
Prevalence of Liver Steatosis in Axial Spondyloarthritis : A Retrospective Study Using Computed Tomography Liver Minus Spleen Attenuation Ratio
Léa Da silva¹, olivier Fakih¹, mickael chouk¹, delphine weil-verhoeven², DANIEL WENDLING³, CLEMENT PRATI⁴ and FRANK VERHOEVEN¹, ¹Service de rhumatologie, CHU de Besancon, Besançon, France, ²Service d'hépatologie, CHU de Besancon, Besançon, France, ³University Hospital, Besançon, France, ⁴Service de Rhumatologie, centre hospitalier régional universitaire Jean-Minjoz, Université de Franche-Comté, Besançon, France
Background/Purpose: The management of axial spondyloarthritis (axSpA) comorbidities includes the metabolic syndrome (2). The latter includes steatotic liver disease (SLD) (3), which is present in…

« Previous Page
1
…
3
4
5
6
7
…
41
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].